Popular terms

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      

This page is updated frequently with new Cytokine-related patent applications.




Date/App# patent app List of recent Cytokine-related patents
04/07/16
20160095954 
Fibrin microthreads
Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute


04/07/16
20160095912 
Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095911 
Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095892 
Sour cherry topical biotherapeutic formulations, manufacture and treatment of human osteoarthritis symptoms
A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by cd3+ t lymphocytes in a vertebrate mammal.. .

03/31/16
20160091486 
Glatiramer acetate human monocytic cell line-based potency assay
The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (ifnγ), exposing said cells to said batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine sil-1ra or the viability of said cells induced by glatiramer acetate.. .
Synthon B.v.


03/31/16
20160089426 
Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089425 
Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089424 
Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/24/16
20160083442 
Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use
In t lymphocytes, p38 mitogen activated protein kinase (mapk) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and dna damage-inducible alpha (gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in t cells.
The U.s.a, As Represented By The Secretary Department Of Health And Human Services


03/24/16
20160082092 
Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh


03/24/16
20160082085 

Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer


The present invention relates to a combination of a parvovirus and a cytokine, preferably ifny, for use in treating pancreatic cancer, in particular a terminal stage of this disease.. .
Ruprecht-karls-universitaet Heidelberg


03/24/16
20160081958 

Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response


Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (mso). The mso may be l-methionine s-sulfoximine (lsmso), l-methionine r-sulfoximine (lrmso), or diastereomeric mixture of lsmso and lrmso.

03/24/16
20160081913 

Composition for stimulating hair growth or preventing hair loss which includes extract neural stem cell and producing same


The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (nscs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth.
Korea University Research And Business Foundation


03/24/16
20160081329 

Modulating ischemic injury and preserving/storing tissue


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


03/17/16
20160077107 

Personalised medicine


The present invention relates to a method for assessing the efficacy of an inhibitor of a pro-inflammatory cytokine and/or of b cells in a subject and a method for treating said subject with said inhibitor provided the efficacy of said inhibitor has been determined as sufficient.. .
Stichting Katholieke Universiteit


03/17/16
20160077102 

Diagnostic biomarker to predict women at risk for preterm delivery


The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery.
Cedars-sinai Medical Center


03/17/16
20160075996 

Method for producing nk cell-enriched blood preparation


It is intended to provide a method for producing an nk cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing nk cells, etc. In blood collected from an organism.
Biotherapy Institute Of Japan


03/17/16
20160075739 

Peptide for inducing mast cell-specific apoptosis and use thereof


A peptide according to the present invention can perform a function identical or similar to the function of natural ctla-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (cd80 and cd86) to inhibit activity of t cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, il-2 and ifn-γ).
Caregen Co., Ltd.


03/17/16
20160074537 

Immunoconjugates for the treatment of tumours


A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (ttm) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.. .
Molmed Spa


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074437 

Immunological treatment of liver failure


Disclosed are means of treatment of liver failure and augmentation of liver regeneration by utilization of immune modulation through administration of immunocytes and mesenchymal stem cells. In one embodiment liver failure is treated by cord blood mononuclear cells administered allogeneic to the host that have been pretreated with hepatogenic cytokines..
Batu Biologics, Inc.


03/10/16
20160070884 

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.


03/10/16
20160069882 

Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis


The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases.
Albert-ludwigs-universitÄt Freiburg


03/10/16
20160068584 

Cytokine derived treatment with reduced vascular leak syndrome


The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an il-15 derivative conjugate so as to induce a proliferation of natural killer cells (nk cells) which is the same or higher than the one obtained with high dose of interleukin-2 (hdil-2); eventually associated with a pharmaceutically acceptable carrier.. .
Institut Gustave Roussy (igr)


03/10/16
20160067357 

Detection of high risk drusen


In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided.
Apellis Pharmaceuticals, Inc.


03/10/16
20160067356 

Genetically modified human natural killer cell lines


The invention provides a natural killer cell, nk-92, modified to express an fc receptor on the surface of the cell, such as cd 16 (fcγriii-a), or other fcγ or fc receptors. The modified nk-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as fcεri-γ,tcr-ζ, or to concurrently express interleukin-2 (il-2) or other cytokines.
Fox Chase Cancer Center


03/10/16
20160067284 

Method for producing sheet-shaped cell culture


A sheet-shaped cell culture and method for producing a sheet-shaped cell culture are disclosed having a high activity such as high cytokine productivity and a production method thereof. The method for producing a sheet-shaped cell culture can include freezing cells, thawing the frozen cells and forming a sheet-shaped cell culture.
Terumo Kabushiki Kaisha


03/10/16
20160067270 

Use of ginsenoside f2 for prophylaxis and treatment of liver disease


Provided are use of ginsenoside f2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside f2. Ginsenoside f2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory t cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine il-10 in regulatory t cells, and inhibits differentiation of naive t cells into th17 cells, and is thereby effectively used for the treatment of various liver diseases..
Intelligent Synthetic Biology Center


03/03/16
20160060323 

Zcytor17 heterodimeric cytokine receptor


Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto..
Zymogenetics, Inc.


03/03/16
20160060314 

Development of a protein-based biotherapeutic agent that penetrates cell-membrane and induces anti-tumor effect in solid tumors - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-tumor compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060313 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-angiogenic effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-angiogenic compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060312 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-pancreatic cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-pancreatic cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060311 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-lung cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-lung cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060310 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-hepatocellular carcinoma effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-hepatocellular carcinoma compositions comprising the same


Protein transduction exploits the ability of some cell-penetrating peptide (cpp) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic cpps, named membrane translocating sequence (mts), membrane translocating motif (mtm) and macromolecule transduction domain (mtd), are able to deliver biologically active proteins into a variety of cells and tissues.
Cellivery Therapeutics, Inc.


03/03/16
20160058835 

Use of taenia solium recombinant calreticulin for inducing interleukin-10 expression


The present invention is related to the use of a recombinant protein to induce interleukin 10 expression, wherein the protein is taenia solium parasite recombinant calreticulin (rtscrt) formulated in a physiologic glycosated solution orally or parenterally administered. The used methodology for rtscrt expression and purification described in present invention, resulted in a recombinant protein expressed without post-translational modifications having regulatory immunological effects and capable of stimulating the mrna transcription levels which codify for il-4 and il-10 cytokines.
Universidad Nacional AutÓnoma De MÉxico


03/03/16
20160058798 

Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree


A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated.
University Of Miami


02/25/16
20160053008 

Antibodies that bind both il-17a and il-17f and methods of using same


The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease.
Zymogenetics, Inc.


02/25/16
20160051642 

Treatment of peyronie's disease


The invention relates to systems and therapeutic methods to reduce plaque causing peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque.
Ams Research, Llc


02/18/16
20160047795 

In vitro assessing cytokine storm responses


The present disclosure an in vitro method of assaying the stimulation of a cytokine storm response comprising the steps of: a. Co-culturing pbmcs and matched differentiated endothelial cells to provide a system representative of human responses in vivo, and b.
Imperial Innovations Ltd


02/18/16
20160046710 

Notch2 binding molecules for treating respiratory diseases


The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease.
Novartis Ag


02/18/16
20160046611 

Novel chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders


The present invention relates to novel chromone alkaloid of formula 1 isolated from the plant dysoxylum binectariferum. The compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4h-chromen-4-one, is found to be a potential inhibitor of cell growth and proliferation and also inhibits production of pro-inflammatory cytokines.
Council Of Scientific & Industrial Research


02/18/16
20160045597 

Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1


The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human cd40; and a pd-l1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.. .
Hoffmann-la Roche Inc.


02/18/16
20160045548 

Method for treating cancers with dendritic killer cells and pharmaceutical composition comprising the same


The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is il-15.
Fullhope Biomedical Co., Ltd


02/18/16
20160045517 

Treating auto-immune and auto-inflammatory diseases


The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (il-17 or il-17a) levels in both broncheoalveolar lavage fluid (balf) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (mapk) activity involving the use of 17α-hydroxyprogesterone caproate (17-ohpc) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-ohpc, and the formulation may be used in a method to treat il-17 cytokine and/or p38 mapk mediated auto-immune and auto-inflammatory diseases.
Prairie Pharmaceuticals Llc


02/18/16
20160045396 

Pulmonary delivery of progestogen


The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-ohpc) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-ohpc as taught herein may be used to reduce cytokine interleukin-17 (il-17 or il-17a) levels in both broncheoalveolar lavage fluid (balf) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (mapk) activity.
Prairie Pharmaceuticals Llc


02/11/16
20160039928 

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17 a. The disclosure more specifically relates to specific antibodies and proteins that are il-17 a antagonists (inhibit the activities of il-17 a and il-17 af) and are capable of inhibiting il-17 a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag


02/11/16
20160039920 

Antibody-drug conjugates


The invention relates to an antibody-drug conjugate and an immunocytokine for use in the treatment of a neoplastic or inflammatory disease, as well as molecules comprising an antibody-drug conjugate and an immunocytokine.. .
Philogen S.p.a.


02/11/16
20160039905 

B7-h4 fusion proteins and methods of use thereof


Fusion proteins containing b7-ii4 polypeptides are disclosed. The b7-h4 fusion proteins can include full-length b7-h4 polypeptides, or can contain a fragment of a full-length b7-h4 polypeptide, including some or all of the extracellular domain of the b7-h4 polypeptide.
Amplimmune, Inc.


02/11/16
20160038541 

Induced dendritic cells and uses thereof


The present invention relates to cells engineered to express at least one cytokine and at least one antigen which induces the self differentiation of dendritic cell (dc) progenitor cells into functional antigen-presenting induced dc (idc). Moreover, therapeutic uses of said idc for regenerating the immune system after transplantation of hematopoietic stem cells are disclosed.
Medizinische Hochschule Hannover


02/11/16
20160038535 

Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia


The invention relates to pharmaceutical compositions and treatment regimes useful in treating one or more of the following conditions: inflammation, kidney disease, eye disease, end-organ injury, systemic endotoxemia, and/or vitamin d resistance. The compositions and treatment regimes are also useful in reducing elevated crp levels and/or elevated pro-inflammatory cytokines.

02/04/16
20160033482 

Biological specimen evaluation methods using cytology and immunology


Information on cytokines and cytology obtained from a biological specimen are combined as a method of predicting the risk that dysplasia will progress to cancer. Methods are disclosed herein to augment the evaluation of biological samples from subjects being tested for cancer.
Cytocore, Inc.


02/04/16
20160031795 

Curcumin analogues as zinc chelators and their uses


Wherein α, β, x, y, and r1-r11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (mmp), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting nfκ-b activation in a population of cells..

02/04/16
20160030736 

Methods and bilateral renal neuromodulation


Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


02/04/16
20160030512 

Combination preparation comprising a cytokine antagonist and corticosteroid


The present invention relates to the treatment of patients with pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated..
Orthogen Ag


02/04/16
20160030476 

Compositions, methods and devices for promoting wound healing and reducing infection


Compositions, methods and devices are provided for promoting healing and preventing and treating infection in mammalian subjects. The compositions include pharmacologically active, protease inhibiting, cytokine protecting, aqueous media soluble sulfonated materials, optionally associated with one or more secondary therapeutic agents or carriers, to reduce one or more of inflammation, bacterial proliferation and proteolytic activity.
Iasis Molecular Sciences


02/04/16
20160030332 

2-fluoro-modified rnas as immunostimulators


Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5′ triphosphate, 2′ fluoro-modified pyrimidine non-linear single stranded rna at least 17 nucleotides long with a least 3 base pairings or a 5′ triphosphate, 2′ fluoro-modified double stranded rna at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject.
Duke University


01/28/16
20160024504 

Treating th2-mediated diseases by inhibition of bromodomains


The invention provides methods for treating th2 cytokine-mediated diseases by inhibiting bromodomain function.. .
Genentech, Inc.


01/28/16
20160024472 

Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines


The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only gm-csf without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as il-4 or il-13, to prevent differentiation into a non-dendritic cell lineage.
Northwest Biotherapeutics, Inc.


01/28/16
20160022772 

Cytokine receptors as targets for hypertension therapy and methods of use


The present disclosure provides methods of treating or ameliorating hypertension in a subject comprising administering a therapeutically effective amount of an il-1 receptor antagonist.. .
Duke University


01/28/16
20160022748 

Recombinant vsv for the treatment of tumor cells


The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides vsv vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said vsv vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type vsv vector.
University Of Miami


01/28/16
20160022616 

Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells


The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors.

01/21/16
20160018401 

Methods of prognosis


The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (mic-1) in a test body sample such as serum..
St Vincent's Hospital Sydney Limited


01/21/16
20160017277 

Cell culture media composition and methods of producing thereof


A serum free cell culture media, wherein the media is adapted to be conditioned by culturing a first set of eukaryotic cells in the media, wherein the first set of eukaryotic cells use an expression vector to excrete levels of desired complex proteins into the media; wherein said desired complex proteins include human growth hormone (hgh), growth hormone-like growth factors, insulin-like growth factors, insulin, modified insulins, cytokines, mitogenic proteases and mixtures thereof; and wherein the media is adapted to grow a set of eukaryotic cells.. .
Neuclone Biologics Pty Ltd


01/21/16
20160015785 

Modulating ischemic injury


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


01/21/16
20160015749 

Engager cells for immunotherapy


Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule.
Celgene Corporation


01/14/16
20160011192 

Method and kit for cytokine analysis from a human whole blood sample


The invention further relates to an associated diagnostic kit and to the use thereof. The invention is applied in medical diagnostics and medical research..

01/14/16
20160010061 

Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting nox-1


Methods of preserving and/or protecting pancreatic beta cells by inhibiting nox-1. In a further aspect, nox-1 inhibitors are administered to a subject in order to preserve and/or protect beta cells in the prevention or treatment of diabetes.
Eastern Virginia Medical School


01/14/16
20160008438 

Composition for preventing or treating sepsis


Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of tnf, il-1, and il-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.
Kael-gemvax Co., Ltd.


01/07/16
20160003804 

Compositions and methods for modulating c-rel-dependent cytokine production


The present invention is directed to compositions and methods for modulating c-rel-dependent cytokine production without materially altering the level of expression of nfκb and/or the amount of iκb. The present invention is also directed to screening for modulators of c-rel activity as determined by assaying for altered subcellular localization of c-rel but where the level of expression of nfκb and/or the amount of iκb is materially unaltered..
Synta Pharmaceuticals Corporation


01/07/16
20160002340 

Zcytor17 heterodimeric cytokine receptor monoclonal antibodies


Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto..
Zymogenetics, Inc.


01/07/16
20160000877 

Compositions and methods for modulating gamma-c-cytokine activity


The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000874 

Modulating ischemic injury


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


01/07/16
20160000867 

Compositions and methods for modulating the immune system


A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc


01/07/16
20160000842 

Oncolytic virus


Embodiments of the present disclosure concern oncolytic viruses, such as vaccinia virus, for example, for the treatment of cancer, wherein the viruses encode an engager molecule having an activation domain that recognizes a cell molecule, such as cd3, for example, on t cells and an antigen recognition domain that recognizes a tumor antigen, such as epha2, her2, gd2, or glypican-3, for example. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.
Baylor College Of Medicine


12/31/15
20150376707 

Methods of diagnosing and treating inflammatory bowel disease


The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and crohn's disease.
Cedars-sinai Medical Center




Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6941

4469

0 - 1 - 101